Publications

Evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents tested against over 2,000 clinical isolates from 22 medical centers in Japan. Japan Antimicrobial Resistance Study Group. by Yamaguchi K, Mathai D, Biedenbach DJ, Lewis MT, Gales AC and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 34 (2): 123-134

Methods for improved detection of oxacillin resistance in coagulase- negative staphylococci: Results of a multicenter study. by Tenover FC, Jones RN, Swenson JM, Zimmer B, McAllister S and Jorgensen JH published in J. Clin. Microbiol. 1999; 37 (12): 4051-4058

International surveillance of blood stream infections due to Candida species in the European SENTRY Program: Species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY Participant Group (Europe). by Pfaller MA, Jones RN, Doern GV, Fluit AC, Verhoef J, Sader HS, Messer SA, Houston A, Coffman S and Hollis RJ published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 19-25

Multicenter evaluation of the antimicrobial activity for seven broad-spectrum β-lactams in Turkey using the Etest method. Turkish Antimicrobial Resistance Study Group. by Pfaller MA, Korten V, Jones RN and Doern GV published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 65-73

Multicenter evaluation of the antimicrobial activity for six broad- spectrum β-lactams in Venezuela: Comparison of data from 1997 and 1998 using the Etest method. Venezuelan Antimicrobial Resistance Study Group. by Pfaller MA, Jones RN and Doern GV published in Diagn. Microbiol. Infect. Dis. 1999; 35 (2): 153-158

Multicenter evaluation of antimicrobial resistance to six broad- spectrum β-lactams in Colombia: Comparison of data from 1997 and 1998 using the Etest method. The Colombian Antimicrobial Resistance Study Group. by Pfaller MA, Jones RN, Doern GV and Salazar JC published in Diagn. Microbiol. Infect. Dis. 1999; 35 (3): 235-241

In vitro evaluation of cefepime and other broad-spectrum β-lactams in 22 medical centers in Japan: A phase II trial comparing two annual organism samples. The Japan Antimicrobial Resistance Study Group. by Lewis MT, Yamaguchi K, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 307-315

Antimicrobial activity and spectrum of SCH27899 (Ziracin) tested against Gram-positive species including recommendations for routine susceptibility testing methods and quality control. Quality Control Study Group. by Jones RN, Marshall SA and Erwin ME published in Diagn. Microbiol. Infect. Dis. 1999; 34 (2): 103-110

Contemporary antimicrobial susceptibility patterns of bacterial pathogens commonly associated with febrile patients with neutropenia. by Jones RN published in Clin. Infect. Dis. 1999; 29 (3): 495-502

Summation: β-lactam resistance surveillance in the Asia-Western Pacific region. by Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 333-338

In vitro evaluation of broad-spectrum β-lactams in the Philippines medical centers: Role of fourth-generation cephalosporins. The Philippines Antimicrobial Resistance Study Group. by Johnson DM, Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 291-297

Comparative activity of clinafloxacin and nine other compounds tested against 2,000 contemporary clinical isolates from patients in United States hospitals. by Deshpande LM, Diekema DJ, and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (1): 81-88

In vitro evaluation of cefepime and other broad-spectrum β-lactams in Taiwan medical centers. The Taiwan Antimicrobial Resistance Study Group. by Biedenbach DJ, Johnson DM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 299-305

In vitro evaluation of cefepime and other broad-spectrum β-lactams in eight medical centers in Thailand. The Thailand Antimicrobial Resistance Study Group. by Biedenbach DJ, Johnson DM and Jones RN published in Diagn. Microbiol. Infect. Dis. 1999; 35 (4): 325-331

Antimicrobial activity and spectrum investigation of eight broad-spectrum beta-lactam drugs: A 1997 surveillance trial in 102 medical centers in the United States. Cefepime Study Group. by Jones RN, Pfaller MA, Doern GV, Erwin ME and Hollis RJ published in Diagn. Microbiol. Infect. Dis. 1998; 30 (3): 215-228

Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada. by Jones RN, Ballow CH, Biedenbach DJ, Deinhart JA and Schentag JJ published in Diagn. Microbiol. Infect. Dis. 1998; 31 (3): 437-451

Comparative antimicrobial activity of trovafloxacin tested against 3,049 Streptococcus pneumoniae isolates from the 1997-1998 respiratory infection season. by Jones RN, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (2): 119-126

Antimicrobial activity of gatifloxacin tested against 1,676 strains of ciprofloxacin-resistant Gram-positive cocci isolated from patient infections in North and South America. by Jones RN, Beach ML, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1998; 32 (3): 247-252

Multicenter evaluation of the in vitro activity of six broad-spectrum β-lactam antimicrobial agents in Puerto Rico. The Puerto Rico Antimicrobial Resistance Study Group. by Doern GV, Jones RN, Pfaller MA, Erwin M and Ramirez-Rhonda C published in Diagn. Microbiol. Infect. Dis. 1998; 30 (2): 113-119

Multicenter evaluation of the antimicrobial activity for six broad- spectrum β-lactams in Venezuela using the Etest method. The Venezuelan Antimicrobial Resistance Study Group. by Pfaller MA, Jones RN and Doern GV published in Diagn. Microbiol. Infect. Dis 1998; 30 (1): 45-52

National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE Program. by Pfaller MA, Jones RN, Messer SA, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1998; 31 (1): 327-332

Inducible Amp-C β-lactamase producing Gram-negative bacilli from blood stream infections: Frequency, antimicrobial susceptibility, and molecular epidemiology in a national surveillance program (SCOPE). by Pfaller MA, Jones RN, Marshall SA, Coffman SL, Hollis RJ, Edmond MB and Wenzel RP published in Diagn. Microbiol. Infect. Dis. 1997; 28 (4): 211-219

Antimicrobial interactions (synergy) of teicoplanin with two broad-spectrum drugs (cefotaxime, ofloxacin) tested against Gram-positive isolates from Germany and the United States. by Jones RN, Marshall SA and Grimm H published in Diagn. Microbiol. Infect. Dis. 1997; 29 (2): 87-94

Multicenter evaluation of antimicrobial resistance to six broad-spectrum β-lactams in Colombia using the Etest method. The Colombian Antimicrobial Resistance Study Group. by Jones RN, Salazar JC, Pfaller MA and Doern GV published in Diagn. Microbiol. Infect. Dis. 1997; 29 (4): 265-272

Antimicrobial susceptibility of Klebsiella pneumoniae producing extended-spectrum beta-lactamase (ESBL) isolated in hospitals in Brazil. by Gales AC, Bolmstrom A, Sampaio J, Jones RN and Sader HS published in Braz. J. Infect. Dis. 1997; 1 (4): 196-203

Impact of changing pathogens and antimicrobial susceptibility patterns in the treatment of serious infections in hospitalized patients. by Jones RN published in Am. J. Med. 1996; 100 (6A): 3S-12S

Emerging multiply resistant enterococci among clinical isolates. I. Prevalence data from 97 medical center surveillance study in the United States. Enterococcus Study Group. by Jones RN, Sader HS, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1995; 21 (2): 85-93

Canadian ofloxacin susceptibility study: A comparative study from 18 medical centers. Canadian Ofloxacin Study Group. by Hoban DJ and Jones RN. published in Chemotherapy 1995; 41 (1): 34-38

North American (United States and Canada) comparative susceptibility of two fluoroquinolones: ofloxacin and ciprofloxacin. A 53-medical-center sample of spectra of activity. North American Ofloxacin Study Group. by Jones RN and Hoban DJ published in Diagn. Microbiol. Infect. Dis. 1994; 18 (1): 49-56

Prevalence of important pathogens and antimicrobial activity of parenteral drugs at numerous medical centers in the United States, I. Study on the threat of emerging resistances: Real or perceived? Fluoroquinolone Resistance Surveillance Group. by Jones RN, Kehrberg EN, Erwin ME and Anderson SC published in Diagn. Microbiol. Infect. Dis. 1994; 19 (4): 203-215

Fluoroquinolone (lomefloxacin) international surveillance trial: A report of 30 months of monitoring in vitro activity. by Jones RN published in Am. J. Med. 1992; 92 (4A): 52S-57S

Ofloxacin, a new broad-spectrum fluoroquinolone. Results from a multicenter, national comparative activity surveillance study. The Ofloxacin Surveillance Group. by Jones RN, Reller LB, Rosati LA, Erwin ME and Sanchez ML published in Diagn. Microbiol. Infect. Dis. 1992; 15 (5): 425-434

The prevalence of staphylococcal resistance to penicillinase-resistant penicillins. A retrospective and prospective national surveillance trial of isolates from 40 medical centers. by Jones RN, Barry AL, Gardiner RV and Packer RR published in Diagn. Microbiol. Infect. Dis. 1989; 12 (5): 385-394

Statistical criteria for selecting quality control limits for broth microdilution susceptibility tests with 39 different antimicrobial agents. Collaborative Antimicrobial Susceptibility Testing Group. by Barry AL, Fuchs PC and Jones RN published in Diagn. Microbiol. Infect. Dis. 1989; 12 (5): 413-420